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ABSTRACT 
The purpose of this study was to examine the influence of previous infection with cytomegalovirus 
(CMV) or Epstein Barr virus (EBV) on the incidence, severity and duration of upper respiratory tract 
illness (URTI) episodes in endurance athletes during a 4-month winter training period. Blood samples 
were obtained from 236 healthy subjects (186 males, 70 females) who were engaged in regular sports 
training (predominantly endurance-based activities such as running, cycling, swimming, triathlon, 
team games and racquet sports) at the start of the study period for CMV and EBV serostatus analysis. 
Their baseline characteristics were (mean ± SD) age: 21 ± 2 years, body mass: 73.5 ± 11.2 kg, height: 
176.5 ± 9.3 cm, body mass index 23.6 ± 2.2 kg/m2. Weekly training and daily illness logs were kept. 
Self-reported weekly training duration averaged 9.6 ± 5.2 h/week and 4.0 ± 1.6% of the cohort 
experienced a URTI episode each week. Twenty-five percent of the subject cohort were CMV positive 
with a similar proportion in males (24%) and females (26%) whereas 84% of the subject cohort were 
EBV positive with a similar proportion in males (84%) and females (83%). In addition, 21% of the 
subject cohort were both CMV and EBV positive (CMV+EBV+) whereas 13% of the subject cohort had 
no prior CMV or EBV infection (CMV-EBV-). With regard to CMV/EBV serostatus, the results 
indicated that there was no difference in the proportion of subjects who presented with symptoms of 
infection between CMV/EBV positive and negative groups. Athletes with previous CMV infection 
had fewer URTI symptom days during the study period than those with no previous infection [mean 
and interquartile range (IQR), positives 2 (0-7) days, negatives 4 (1-9) days, P = 0.033] and EBV 
serostatus had no influence on URTI episode incidence, severity or duration. Moreover, we found 
that athletes with prior infection of both CMV and EBV had fewer URTI episodes and symptom days 
than athletes who were seronegative for both CMV and EBV [mean (IQR), URTI episodes: positives 0 
(0-1), negatives 1 (0-2), P = 0.04; symptom days: positives 2 (0-7), negatives 8 (2-12), P = 0.01]. The 
reasons for this are still unclear but could be related to the previously reported elevated T cytotoxic 
cell response to exercise in individuals with positive CMV serostatus. Previous coinfection with CMV 
and EBV might promote protective immune surveillance to lower the risk of URTI.  
 
